Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.

The European Commission’s decision is based on two Phase III trials where Tevimbra plus chemotherapy improved overall ...

Bevacizumab biosimilars have the potential to expand access and reduce costs without compromising patient outcomes in ...

Tiragolumab missed the chance to prove a survival benefit in SKYSCRAPER-01 adding to previous trial failures for the ...

ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual ...

Oct. 9, 2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 ... Scientists Discover That ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

China NMPA accepts Akeso's sNDA penpulimab combination therapy for first-line treatment of hepatocellular carcinoma: Hong Kong Monday, November 25, 2024, 13:00 Hrs [IST] Akeso, In ...

PulmoCheck is a Streamlit application designed to help users assess the risk factors associated with lung cancer based on various symptoms and patient data. This app provides tools for predictive ...

Lung cancer remains the most frequently diagnosed cancer globally, with 2.5 million new cases, representing 12.4% of all ...